

Original Article

***Dientamoeba fragilis* diagnosis by fecal screening: relative effectiveness of traditional techniques and molecular methods**

Negin Hamidi¹, Ahmad Reza Meamar¹, Lamah Akhlaghi¹, Zahra Rampisheh^{2,3}, Elham Razmjou¹

¹ Department of Medical Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

² Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran

³ Department of Community Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: *Dientamoeba fragilis*, an intestinal trichomonad, occurs in humans with and without gastrointestinal symptoms. Its presence was investigated in individuals referred to Milad Hospital, Tehran.

Methodology: In a cross-sectional study, three time-separated fecal samples were collected from 200 participants from March through June 2011. Specimens were examined using traditional techniques for detecting *D. fragilis* and other gastrointestinal parasites: direct smear, culture, formalin-ether concentration, and iron-hematoxylin staining. The presence of *D. fragilis* was determined using PCR assays targeting 5.8S rRNA or small subunit ribosomal RNA.

Results: *Dientamoeba fragilis*, *Blastocystis* sp., *Giardia lamblia*, *Entamoeba coli*, and *Iodamoeba butschlii* were detected by one or more traditional and molecular methods, with an overall prevalence of 56.5%. *Dientamoeba* was not detected by direct smear or formalin-ether concentration but was identified in 1% and 5% of cases by culture and iron-hematoxylin staining, respectively. PCR amplification of SSU rRNA and 5.8S rRNA genes diagnosed *D. fragilis* in 6% and 13.5%, respectively. Prevalence of *D. fragilis* was unrelated to participant gender, age, or gastrointestinal symptoms.

Conclusions: This is the first report of molecular assays to screen for *D. fragilis* in Iran. The frequent finding of *D. fragilis* via fecal analysis indicated the need to include this parasite in routine stool examination in diagnostic laboratories. As the length of amplification target correlates to the sensitivity of PCR, this assay targeting the *D. fragilis* 5.8S rRNA gene seems optimal for parasite detection and is recommended in combination with conventional microscopy for diagnosing intestinal parasites.

Key words: *Dientamoeba fragilis*; intestinal parasites; PCR; Iran.

J Infect Dev Ctries 2018; 12(1):052-059. doi:10.3855/jidc.9643

(Received 31 July 2017 – Accepted 05 december 2017)

Copyright © 2018 Hamidi *et al.* This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Dientamoeba fragilis Jepps and Dobell 1918 (*Monocercomonadidae*, Sarcocystidophora) is a trichomonad parasite infecting the gastrointestinal tract of humans and other vertebrates, including sheep, pigs, and birds [1,2]. This microorganism shows extensive genetic diversity, comprising variants morphologically related but distinct in their pathogenicity [3-5]. Although described about century ago, *D. fragilis* biology, virulence, pathogenicity, epidemiology, and mode of transmission are not well understood, and findings can be conflicting [4,6,7].

Dientamoeba fragilis infections range from asymptomatic to causing acute or chronic disease in children and adults. The most common symptom of dientamoebiasis is diarrhea, followed by abdominal pain, fatigue, anorexia, and flatulence [8-10]. Dientamoebiasis may occur at any age and has a

cosmopolitan distribution. Prevalence of *D. fragilis* infection varies considerably and is influenced by factors including geographic location, population density, living conditions, and level of hygiene and sanitation [1]. Data on the international prevalence of *D. fragilis* are limited. Worldwide, the prevalence has been reported to range from 0.4% to 71% [2,8,11,12], making it a more frequent cause of gastrointestinal infection than *Giardia lamblia* [13-15]. The sensitivity of diagnostic techniques and the expertise of testing laboratories affect the reported prevalence rate of *D. fragilis* [14,16]. Common methods such as direct smear and culture are challenging and require experience to distinguish *D. fragilis* from other gastrointestinal parasites [17]. Accurate identification depends on detection of the trophozoites in permanently stained stool smears, since the nuclear structure cannot be demonstrated in unstained stool samples [18]. The

staining technique is generally laborious, time consuming, and relatively insensitive. The development of PCR has provided a highly sensitive and specific method for diagnosis of pathogenic protozoa. PCR-based assays using species-specific primers offer a convenient and reliable technique for the detection of *D. fragilis* [17,19].

Intestinal parasitic infections are a critical public health problem in Iran; however, research on *D. fragilis* has been limited. Its reported prevalence, as determined by the direct smear method, varies from 0.5 to 2.4% depending on area of the country [20-22]. Using the iron-hematoxylin staining method, Jamali and Khademvatan [23] reported prevalence of 13.2%. As *D. fragilis* is a significant human pathogen, further research on its occurrence and effects is warranted [2,24]. We therefore aimed to investigate *D. fragilis* infection in individuals referred to Milad Hospital in Tehran, comparing traditional and molecular methods of detection.

Methodology

Sample collection

In a cross-sectional study, three fresh fecal specimens, separated by at least one day, were collected from each of the 200 participants referred to the clinical laboratory of Milad Hospital in Tehran, from March through July 2011. Participants provided informed consent and the study was approved by Ethics Committee under number IR.IUMS.FMD.REC 1390.1065. Fecal specimens were immediately submitted to the research laboratory of the Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences. All specimens were investigated for parasites by direct wet-mount microscopy, formalin-ether concentration, culture, modified iron-hematoxylin staining, and two PCR assays for *D. fragilis*.

Microscopic examination

Direct wet-mount microscopy and formalin-ether concentration methods

Stool specimens were investigated microscopically for trophozoites forms of intestinal protozoan parasites using direct wet-mount in saline and iodine-solution (Lugol's iodine) [10]. Formalin-ether concentration was conducted to identify ova and cysts or oocysts [25,26].

Sample preparation and culture

To a 10-20 g fecal sample, 50 mL of phosphate buffered saline (PBS) pH 7.4 was added and thoroughly mixed. The suspension was filtered through two layers

of gauze and centrifuged at $800 \times g$ for 5 min. Sediments were re-suspended in ~2 mL of PBS before combining with culture medium and fixing in either sodium acetate-acetic acid-formalin (SAF) or 80% ethanol [27-29].

For isolation of intestinal protozoa to be cultivated in an axenic medium, feces were cultured in a diphasic medium as described by Clark and Diamond [30]: slope of heat-inactivated horse serum (kindly provided by the Faculty of Veterinary Medicine, University of Tehran, Iran) overlaid with 5 mL of Ringer's solution and supplemented with ~1 mg rice starch (HSr+S). Penicillin-streptomycin (Sigma-Aldrich, Steinheim, Germany) was added to control the growth of human bacterial flora. A 300 μ L sample of washed and unpreserved stool were added to culture tubes containing medium and rice starch and incubated in a vertical position at 35.5 °C. A drop of sediment from the tube was examined on a microscope slide three times at 48 hours intervals at 100 \times and 400 \times magnification.

Staining

The stool samples fixed in SAF were stained with modified iron-hematoxylin stain according to methods for identification of protozoa [9,27,31]. Precise microscopic diagnosis of *D. fragilis* was based on morphological characters from permanent stained smears at 400 \times and 1000 \times magnification. All slides were examined by two independent examiners.

Molecular examination

DNA extraction

One mL of stool preserved in 80% ethanol was centrifuged at $1000 \times g$ for 5 minutes, and the sediment was re-suspended in PBS and washed twice in sterile PBS to remove ethanol. After washing, the sediment was re-suspended in 200 μ L 2% polyvinylpyrrolidone (PVPP) (Sigma-Aldrich, Steinheim, Germany) in PBS, combined thoroughly, and stored at -20 °C for 24 hours [28]. The samples were heated for 10 minutes at 100 °C before submitting to DNA extraction using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions, modified according to Verweij *et al.* [28].

Polymerase chain reactions

Conventional PCR was performed on samples to amplify a *D. fragilis* 98 bp 5.8S rDNA product [28] and an 887 bp SSU rDNA fragment as previously described [27]. To target 5.8S rRNA, the primers DF-124 (5'-

CAACGGATGTCTTGGCTCTTTA-3') and DF-221 (5'-TGCATTCAAAGATCGAACTTATCAC-3') [28] were used in 15 µL of an amplification reaction mixture with 7.5 µL Taq DNA polymerase 2X-preMix (GeneOn, Germany), 2 µL of genomic DNA, and 0.4 µM of each primer. Reaction conditions were 3 minutes at 95 °C followed by 50 cycles of 95 °C for 15 s and 60 °C for 60 s, with a final extension of 72 °C for 2 minutes. Amplification products were separated on 2.5% (W/V) agarose gel by electrophoresis.

The primers DF400 (5'-TATCGGAGGTGGTAATGACC-3') and DF1250 (5'-CATCTTCCTCCTGCTTAGACG-3') targeting SSU (18S) rRNA [27] in 20 µL final PCR reaction [10 µL of Taq DNA polymerase 2X-preMix (GeneOn, Ludwigshafen, Germany), 2 µL genomic DNA, and 0.4 µM of each PCR primer] with the reaction conditions of 3 minutes at 94 °C followed by 30 cycles of 94 °C for 1 minutes, 57 °C for 1.5 minutes, and 72 °C for 2 minutes and a final step of 7 minutes at 72 °C. The PCR products were detected on ethidium bromide stained 1.5% agarose gels. All PCR reactions included a negative control containing sterile distilled water instead of DNA template and a positive control containing genomic DNA extracted from a stool specimen microscopically confirmed to be infected with *D. fragilis*. Some *D. fragilis* PCR-positive samples were confirmed by sequencing an 887 bp amplified SSU rRNA gene fragment in both directions (MWG-

Biotech Company, Ebersberg, Germany). The sequence results were read by CHROMAS (Technelysium Pty Ltd., Queensland, Australia) and aligned using DNASIS MAX v. 3.0 (Hitachi, Yokohama, Japan). The final SSU rDNA sequencing results were compared with the Genbank database using the BLASTN program (<http://www.ncbi.nlm.nih.gov/BLAST/>). Phylogenetic analysis was performed in MEGA7 (www.megasoftware.net) using the neighbor-joining method, and the evolutionary distances were computed using the Kimura 2-parameter method and a bootstrap value of 1000.

Statistical analysis

Statistical analysis was performed using SPSS 16.0 software (SPSS Inc., Chicago, USA). A descriptive analysis was conducted to determine the prevalence of parasites by gender, age group, clinical symptoms, and reason for referral. Associations between qualitative variables were evaluated using the chi-square (χ^2) test to reveal statistically significant values (p -value < 0.05).

Results

Participant enrollment

Two-hundred participants were enrolled in the study, 50.5% female and 49.5% male. The mean age was 27.6 ± 19.1 years, ranging from one to 79 years. Most participants lived in Tehran Province (86%), with

Table 1. Characteristics and clinical features of participants positive and negative for *D. fragilis*

	Participants			<i>p</i> -value
	Positive n = 27	Negative n = 173	Total n = 200	
Age years (Mean ± SD)	31.7 ± 19.8	26.9 ± 19.0	27.6 ± 19.1	0.23
Gender				
Male (%)	13 (6.5)	86 (43.0)	99 (49.5)	0.88
Female (%)	14 (7.0)	87 (43.5)	101 (50.5)	
Clinical symptoms				
Diarrhea (%)	5 (18.5)	26 (15.0)	31 (15.5)	0.21
Anorexia (%)	2 (7.4)	12 (6.9)	14 (7.0)	0.93
Abdominal pain (%)	8 (29.6)	54 (31.2)	62 (31.0)	0.87
Flatulence (%)	4 (14.8)	27 (15.6)	31 (15.5)	0.92
Cramping (%)	8 (29.6)	38 (22.0)	46 (23.0)	0.92
Nausea (%)	4 (14.8)	11 (6.4)	15 (7.5)	0.42
Vomiting (%)	1 (3.7)	5 (2.9)	6 (3.0)	0.82
Urticaria (%)	2 (7.4)	6 (3.5)	8 (4.0)	0.33
Constipation (%)	0 (0.0)	4 (2.3)	4 (2.0)	0.43
Reason for referral				
Routine exam (%)	14 (12.2)	101 (87.8)	115 (57.5)	0.43
Gastrointestinal disorder (%)	12 (16.0)	63 (84)	75 (37.5)	
Non-gastrointestinal disorder (%)	1 (10.0)	9 (90)	10 (5.0)	
Participant home				
Tehran province (%)	23 (13.4)	149 (86.6)	172 (86.0)	0.54
Other province (%)	4 (14.3)	24 (85.7)	28 (14.0)	

Clinical symptom percentages do not total 100% as some participants had multiple symptoms.

14% referred from other provinces. Participants were categorized according the reason for referral: routine medical examination (115), gastrointestinal symptoms (75), or non-gastrointestinal disorders (10). Gastrointestinal symptoms were diarrhea (41.3%, 31/75), anorexia (18.7%, 14/75), abdominal pain (82.7%, 62/75), flatulence (41.3%, 31/75), cramping (61.3%, 46/75), nausea (20%, 15/75), vomiting (8%, 6/75), and constipation (5.3%, 4/75) (Table 1).


Microscopic analysis

Examination by direct microscopy, formalin-ether concentration, and culture and staining techniques revealed 69 (34.5%; 95% CI: 28.3%–41.3%) participants infected with at least one of the species of intestinal protozoon detected: *Dientamoeba fragilis*, *Blastocystis* sp., *Giardia lamblia*, *Entamoeba coli*, and *Iodamoeba butschlii* (Table 2). Helminth infection was not detected. *Blastocystis* sp. was the most commonly detected protozoon (31.5%; 95% CI: 25.5–38.2%). *Dientamoeba fragilis* was detected in ten (5%; 95% CI: 2.7%–9.0%) and two (1%; 95% CI: 0.3%–3.0%) subjects by modified iron-hematoxylin staining and culture methods, respectively; while no *D. fragilis* infection was found by direct microscopy or formalin-ether concentration methods (Table 2).

Molecular analysis

The PCR assays detected *D. fragilis* in 12 (6%; 95% CI: 3.5%–10.2%) and 27 (13.5%; 95% CI: 9.4%–18.9%) subjects with SSU rRNA and 5.8S rRNA gene amplification, respectively (Table 2). *Dientamoeba fragilis* was diagnosed in 14 (13.9%; 95% CI: 8.4%–21.9%) females and 13 (13.1%; 95% CI: 7.8%–21.2%) males. The mean age of *D. fragilis*-positive patients was 31.7 years (SD = 19.8), ranging from one to 66 years (Table 1). The highest prevalence of *D. fragilis* infection (30%; 95% CI: 10.8%–60.3%) was found in participants 60-79 years of age (Figure 1). *D. fragilis*-positive patients had been referred for clinical symptoms associated with *D. fragilis* (44.4%; 95% CI:

Figure 1. Age distribution of *D. fragilis*-infected patients.



27.6%–62.7%), for routine medical examination (51.9%; 95% CI: 34.0%–69.3%), and for non-gastrointestinal disorders (3.7%; 95% CI: 0.7%–18.3%) (Table 1). Gastrointestinal complaints were diarrhea (18.5%, 5/27), anorexia (7.4%, 2/27), abdominal pain (29.6%, 8/27), flatulence (14.8%, 4/27), cramping (29.6%, 8/27), nausea (14.8%, 4/27), and vomiting (3.7%, 1/27) (Table 1). Chi-square analysis have revealed no relationship among *D. fragilis* infection and gender, age, reason for referral, or clinical symptoms. The age distribution of *D. fragilis*-positive individuals compared to participating individuals is shown in Figure 1.

Microscopic examination and PCR showed 79 (39.0%; 95% CI: 32.5–45.9%) patients with intestinal protozoa. Single parasite infections were observed in 60 (30%; 95% CI: 24.1–36.7%) cases. Nineteen patients (9.5%; 95% CI: 6.2–14.4%) had mixed parasite infections, with 15 (7.5%; 95% CI: 4.6–12.0%) infected with two, and four (2%; 95% CI: 0.8–5.0%) infected with three, parasites (Table 3). Among the 27 *D. fragilis*-infected patients, 14 (51.9%; 95% CI: 34.0–69.3%) were co-infected with other intestinal protozoa. Ten showed double infection with *Blastocystis*. In four,

Table 2. Number positive and prevalence (%) of intestinal parasites in participants referred to the clinical laboratory of Milad Hospital, Tehran, from March to July 2011.

Parasite species	Direct microscopy	Formalin-ether concentration	Culture	Iron-hematoxylin	<i>Dientamoeba</i> PCR		Total infection	95% CI ^a of total
					5.8S rRNA	SSU rRNA		
<i>Dientamoeba fragilis</i>	0 (0)	0 (0)	2 (1)	10 (5)	27 (13.5)	12 (6)	27 (13.5)	9.4–18.9
<i>Blastocystis</i> sp.	21 (10.5)	22 (11)	58 (29)	ND	ND	ND	63 (31.5)	25.5–38.2
<i>Giardia lamblia</i>	2 (1)	2 (1)	0 (0)	ND	ND	ND	2 (1)	0.3–3.6
<i>Entamoeba coli</i>	4 (2)	6 (3)	4 (2)	ND	ND	ND	7 (3.5)	1.7–7.0
<i>Iodamoeba butschlii</i>	3 (1.5)	1 (0.5)	1 (0.5)	ND	ND	ND	3 (1.5)	0.5–4.3
Total	26 (13)	29 (14.5)	58 (29)	10 (5)	27 (13.5)	12 (6)	78 (39)	32.5–45.9

^aCI, Confidence Intervals; ND, not done; Infection percentages do not total 100% as some participants had multiple infections.

triple infection was observed: *Blastocystis* and *G. lamblia* in one, *Blastocystis* plus *E. coli* in two, and *Blastocystis* and *I. butschlii* in one (Table 3).


Sequence analysis of SSU rRNA gene amplicons confirmed the *D. fragilis* infections. The sequences were aligned with the published sequences in GenBank using DNASIS MAX v.3.0; (Hitachi, Yokohama, Japan). The three sequences showed 100% homology without variation and were submitted to DDBJ/EMBL/GenBank databases under accession nos. AB692771–AB692773. The sequences showed a 98% identity with that of the *D. fragilis* genotype 1 accession no. AY730405.1 (Figure 2), with a single substitution of a cytosine with a thymine at position 305 and an extra guanine in nucleotide position 239 of the first nucleotide of AY7304050.1.

Discussion

Gastrointestinal parasitic infections caused by helminths and protozoans are common worldwide and occur in most parts of Iran. Factors including method of sample fixation and examination may bias the diagnosis of *D. fragilis* and other protozoans in stool samples [32]. Identification and differentiation of these parasites by common techniques such as direct smear and formalin-ether concentration has been reported to lack accuracy and to be laborious and time consuming compared to molecular assays [17,27,28,33].

In this study we found *D. fragilis* infections in ~13% of individuals referred to Milad Hospital in Tehran, with no correlation to gender, age, clinical symptoms, or reason for referral. Little information with respect to *D. fragilis* in Iran is available, and this is the first report of molecular diagnosis in the area. The obtained prevalence agreed with the reported prevalence of 0.4% to 71% worldwide, in which observed variations are primarily dependent on diagnostic method, the studied population, and the geographic region [2,12]. The reported prevalence of *D. fragilis* in Iran varies from 0.5% [21,34] by direct

Figure 2. Phylogenetic tree of *D. fragilis* genotypes constructed by neighbor-joining analysis, based on small subunit ribosomal DNA (SSU rDNA) sequences retrieved from this study (AB692771–3) compared with *D. fragilis* genotype 1 (AY730405.1), *D. fragilis* genotype 2 (U37461.1), and *Tritrichomonas foetus* (M81842.1) from Genbank. Bootstrap values obtained from 1000 replicates are indicated on branches in percentage. The length of the scale bar is equivalent to a sequence difference of 1%. The evolutionary distances were computed using the Kimura 2-parameter method and are expressed as the number of base substitutions per site. There were 805 positions in the final dataset. Evolutionary analyses were conducted in MEGA7.



microscopy to 2%-13.2% by iron-hematoxylin staining or trichrome staining in patients with intestinal symptoms [20,22,23]. Ghazanchaei et al. [20] and Sarafraz et al. [22] used nested-PCR to confirm *D. fragilis* identified by permanent staining (2% and 2.4%, respectively).

The impact of diagnostic methods on the reported prevalence of *D. fragilis* was clearly seen in our study. Although three stool samples from each individual were collected at different times to increase the probability of detecting *D. fragilis* and other protozoa [8,27], *D. fragilis* was not detected by direct smear or formalin-ether concentration methods, similar to previous studies [22,35,36]. Two *D. fragilis*-infected subjects (1%) were revealed by the culture method. It may be that the *D. fragilis* present were dead, or there may have been an over-growth of other protozoa in the stool samples that prevented *D. fragilis* replication [19]. The prevalence of *D. fragilis* was 5% with iron-hematoxylin staining.

Table 3. Number of single and multiple infections in participants referred to the clinical laboratory of Milad Hospital Tehran, from March to July 2011.

Parasite species	Single and multiple infections			Total
	1	2	3	
<i>Dientamoeba fragilis</i> (Df)	13	10 (Df+B) ^a	4 (Df+B+Gl/Ec/Ib) ^b	27
<i>Blastocystis</i> sp. (B)	44	15 (B+Df/Ec/Ib) ^c	4 (B+Df+Gl/Ec/Ib)	63
<i>Giardia lamblia</i> (Gl)	1	0	1 (Gl+Df+B) ^d	2
<i>Entamoeba coli</i> (Ec)	2	3 (Ec+B)	2 (Ec+Df+B)	7
<i>Iodamoeba butschlii</i> (Ib)	0	2 (Ib+B)	1 (Ib+Df+B)	3
Number of infected patients	60	15	4	79

^a double infection of *Dientamoeba* with *Blastocystis*; ^b triple infection of *Dientamoeba* and *Blastocystis* with *Giardia* or *E. coli* or *Iodamoeba*; ^c double infection of *Blastocystis* with *Dientamoeba* or *E. coli* or *Iodamoeba*; ^d triple infection of *Giardia*, *Dientamoeba* and *Blastocystis*.

Grendon *et al.* [32] suggested that accurate and reliable detection of *D. fragilis* requires permanently stained preparations of fixed or fresh unpreserved stool specimens. However, the accuracy of this technique is low, as the trophozoites of *D. fragilis* can be easily overlooked due to pale staining of their nuclei, which may resemble those of *Entamoeba* spp. We used ethanol-preserved stool samples for PCR to prevent DNA fragmentation [17,28]. Prevalence varied from 6% when targeting the SSU (18S) rRNA gene to 13.5% with the 5.8S rRNA gene, likely reflecting the different size of amplicons of the 5.8S rRNA (98 bp) and the SSU rRNA (887 bp) genes. Verweij *et al.* [28] indicated that the amplification of large fragments can reduce the sensitivity of PCR for detecting *D. fragilis* directly from stool specimens.

In addition to conflicting reports of *D. fragilis* worldwide prevalence, the influence of gender and age on vulnerability to infection is unclear. Our data showed no significant differences in *D. fragilis* infection associated with gender or age. Nevertheless, the highest rate of *D. fragilis* (30%) was detected in participants 60-79 years. These results may be related to the limited study population, particularly of older participants, or might reflect a correlation of age with *D. fragilis* infection. A more comprehensive study with a broad age distribution is needed to resolve this issue. These limitations aside, this finding is similar to studies showing trends of higher infection rates in adults [9,14,37] and in contrast to some reports suggesting that children are common *D. fragilis* carriers [9,38-40]. Other studies have shown no influence of gender or age on rates of *D. fragilis* infection [10,27]. As in most gastrointestinal infections, direct exposure to the parasite may play a crucial role. Therefore, it is probable that infection by *D. fragilis* is related to poor hygiene regardless of gender or age.

We found high overall prevalence of intestinal parasites (39%), including *D. fragilis*, *Blastocystis* sp., *G. lamblia*, *E. coli*, and *I. butschlii* and their co-infections. The most frequently detected parasite was *Blastocystis* (31.5%) followed by *D. fragilis* (13.5%). The majority of *D. fragilis*-positive individuals showed co-infection with other parasites, most frequently *Blastocystis*. Co-infection of *D. fragilis* with other enteric protozoa, especially *Blastocystis*, has been widely reported [10,26,41] and could support the hypothesis of direct transmission of *D. fragilis* through the fecal-oral route [2,6,19,42]. Neither ova nor larvae of helminths were observed in the examined stool samples using the formalin-ether method, reflecting the decreasing incidence and prevalence of intestinal

helminth infections in Iran during past two decades [43].

The presented data showed no significant relationship between infection with *D. fragilis* and clinical symptoms or reason for referral. Many studies have shown correlation of infection with *D. fragilis* and clinical symptoms [3,8,9,13,39], while others report no relationship between symptomatic infection and this parasite [44-46]. This disparity is not surprising, as manifestations ranging from subclinical to severe gastrointestinal symptoms is typically observed in parasitic enteropathogen infections. This phenomenon is suggested to be related to genetic diversity in *D. fragilis*, resulting in a heterogeneous species [2,4,8,47,48].

Currently, two genotypes are described for *D. fragilis*, with genotype 1 being the most common [48]. The investigation of genetic variation in *D. fragilis* SSU rRNA with respect to geographic area has shown that SSU rRNA gene variation is not sufficient to be used as an epidemiological marker [4,47,48]. The SSU rRNA gene sequencing analysis of three *D. fragilis* isolates were similar and revealed 98% identity between our isolates and two corresponding published reference sequences for *D. fragilis* (accession nos. AY730405.1 and FJ649228.1). These results indicated low level of polymorphism, in agreement with recent studies [47,49].

Conclusions

This study demonstrated high prevalence of *D. fragilis* in Tehran via laboratory fecal analysis. Hence, clinical diagnostic laboratories should include screening for this parasite in routine stool examination. The PCR assay targeting the 5.8S rRNA gene detected a significantly greater number of *D. fragilis*-infected patients than did other analyses and is recommended as an effective tool for the accurate diagnosis of *D. fragilis* that should be employed in combination with microscopic methods to obtain a complete assessment of intestinal parasite infection. The use of these methods will prevent a high number of undiagnosed infections. Therefore, further studies applying this method to obtain accurate data on the prevalence of infection in specific age groups, symptomatic and asymptomatic individuals, other animals, and possibly a population-wide study, are required to ascertain epidemiology, pathogenicity, and transmission routes, as well as to identify reservoirs of *D. fragilis*.

Acknowledgements

This study was funded by Iran University of Medical Sciences and Health Services under grant number P/1065. We acknowledge the help of the staff at the laboratory of Milad Hospital in the stool sample collection. This work represents the MSc dissertation of Negin Hamidi. Part of this work was presented at the 8th European Congress on Tropical Medicine and International Health, Copenhagen, Denmark 2013.

References

- Johnson EH, Windsor JJ, Clark CG (2004) Emerging from obscurity: biological, clinical, and diagnostic aspects of *Dientamoeba fragilis*. *Clin Microbiol Rev* 17: 553–570.
- Stark D, Barratt J, Chan D, Ellis JT (2016) *Dientamoeba fragilis*, the neglected Trichomonad of the human bowel. *Clin Microbiol Rev* 29: 553–580.
- Barratt JLN, Harkness J, Marriott D, Ellis JT, Stark D (2011) A review of *Dientamoeba fragilis* carriage in humans: Several reasons why this organism should be considered in the diagnosis of gastrointestinal illness. *Gut Microbes* 2: 3–12.
- Bart A, van der Heijden HM, Greve S, Speijer D, Landman WJ, van Gool T (2008) Intragenomic variation in the internal transcribed spacer 1 region of *Dientamoeba fragilis* as a molecular epidemiological marker. *J Clin Microbiol* 46: 3270–3275.
- Johnson JA, Clark CG (2000) Cryptic genetic diversity in *Dientamoeba fragilis*. *J Clin Microbiol* 38: 4653–4654.
- Clark CG, Röser D, Stensvold CR (2014) Transmission of *Dientamoeba fragilis*: pinworm or cysts? *Trends Parasitol* 30: 136–140.
- Garcia LS (2016) *Dientamoeba fragilis*, one of the neglected intestinal protozoa. *J Clin Microbiol* 54: 2243–2250.
- Vandenberg O, Peek R, Souayah H, Dediste A, Buset M, Scheen R, Retore P, Zissis G, Van Gool T (2006) Clinical and microbiological features of *dientamoebiasis* in patients suspected of suffering from a parasitic gastrointestinal illness: a comparison of *Dientamoeba fragilis* and *Giardia lamblia* infections. *Int J Infect Dis* 10: 255–261.
- Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J (2010) A review of the clinical presentation of *Dientamoebiasis*. *Am J Trop Med Hyg* 82: 614–619.
- Yakoob J, Jafri W, Beg M, Abbas Z, Naz S, Islam M, Khan R (2010) *Blastocystis hominis* and *Dientamoeba fragilis* in patients fulfilling irritable bowel syndrome criteria. *Parasitol Res* 107: 679–684.
- Ögren J, Van Nguyen S, Nguyen MK, Dimberg J, Matussek A (2016) Prevalence of *Dientamoeba fragilis*, *Giardia duodenalis*, *Entamoeba histolytica/dispar*, and *Cryptosporidium* spp in Da Nang, Vietnam, detected by a multiplex real-time PCR. *APMIS* 124: 529–533.
- Röser D, Simonsen J, Nielsen HV, Stensvold CR, Mølbak K (2013) *Dientamoeba fragilis* in Denmark: epidemiological experience derived from four years of routine real-time PCR. *Eur J Clin Microbiol Infect Dis* 32: 1303–1310.
- Stark DJ, Beebe N, Marriott D, Ellis JT, Harkness J (2006) *Dientamoebiasis*: clinical importance and recent advances. *Trends Parasitol* 22: 92–96.
- Crotti D, D'Annibale ML, Fonzo G, Lalle M, Cacciò SM, Pozio E (2005) *Dientamoeba fragilis* is more prevalent than *Giardia duodenalis* in children and adults attending a day care centre in Central Italy. *Parasite* 12: 165–170.
- Girginkardesler N, Coskun s, Cüneyt Balcıoğlu İ, Ertan P, Ok ÜZ (2003) *Dientamoeba fragilis*, a neglected cause of diarrhea, successfully treated with secnidazole. *Clin Microbiol Infect* 9: 110–113.
- Hussein E, Al-Mohammed H, Hussein A (2009) Genetic diversity of *Dientamoeba fragilis* isolates of irritable bowel syndrome patients by high-resolution melting-curve (HRM) analysis. *Parasitol Res* 105: 1053–1060.
- Stark D, Beebe N, Marriott D, Ellis J, Harkness J (2005) Detection of *Dientamoeba fragilis* in fresh stool specimens using PCR. *Int J Parasitol* 35: 57–62.
- Stark D, Beebe N, Marriott D, Ellis J, Harkness J (2006) Evaluation of three diagnostic methods, including real-time PCR, for detection of *Dientamoeba fragilis* in stool specimens. *J Clin Microbiol* 44: 232–235.
- Calderaro A, Gorrini C, Montecchini S, Peruzzi S, Piccolo G, Rossi S, Gargiulo F, Manca N, Dettori G, Chezzi C (2010) Evaluation of a real-time polymerase chain reaction assay for the detection of *Dientamoeba fragilis*. *Diagn Microbiol Infect Dis* 67: 239–245.
- Ghazanachi A, Shargh S, Shabani M, Najafi M, Nourazarian SM (2012) Detection of *Dientamoeba fragilis* in patients referred to Chaloos medical care centers by nested-polymerase chain reaction (PCR) method. *Afr J Biotechnol* 11: 4079–4082.
- Kia EB, Hosseini M, Nilforoushan MR, Meamar AR, Rezaeian M (2008) Study of intestinal protozoan parasites in rural inhabitants of Mazandaran province, Northern Iran. *Iran J Parasitol* 3: 21–25.
- Sarafraz S, Farajnia S, Jamali J, Khodabakhsh F, Khanipour F (2013) Detection of *Dientamoeba fragilis* among diarrheal patients referred to Tabriz health care centers by nested PCR. *Trop Biomed* 30: 113–118.
- Jamali R, Khademvatan S (2004) The frequency of *Dientamoeba fragilis* in patients referred to clinical laboratories of Tabriz. *Urmia Med J* 15: 9–15.
- Barratt JLN, Banik GR, Harkness J, Marriott D, Ellis JT, Stark D (2010) Newly defined conditions for the in vitro cultivation and cryopreservation of *Dientamoeba fragilis*: new techniques set to fast track molecular studies on this organism. *Parasitology* 137: 1867–1878.
- González-Moreno O, Domingo L, Teixidor J, Gracenea M (2011) Prevalence and associated factors of intestinal parasitisation: a cross-sectional study among outpatients with gastrointestinal symptoms in Catalonia, Spain. *Parasitol Res* 108: 87–93.
- Stark D, Beebe N, Marriott D, Ellis J, Harkness J (2005) Prospective study of the prevalence, genotyping, and clinical Relevance of *Dientamoeba fragilis* infections in an Australian population. *J Clin Microbiol* 43: 2718–2723.
- Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J (2010) Comparison of microscopy, two xenic culture techniques, conventional and real-time PCR for the detection of *Dientamoeba fragilis* in clinical stool samples. *Eur J Clin Microbiol Infect Dis* 29: 411–416.
- Verweij JJ, Mulder B, Poell B, van Middelkoop D, Brienen EAT, van Lieshout L (2007) Real-time PCR for the detection of *Dientamoeba fragilis* in fecal samples. *Mol Cell Probes* 21: 400–404.
- Libman MD, Gyorkos TW, Kokoskin E, MacLean JD (2008) Detection of pathogenic protozoa in the diagnostic laboratory: result reproducibility, specimen pooling, and competency assessment. *J Clin Microbiol* 46: 2200–2205.

30. Clark CG, Diamond LS (2002) Methods for cultivation of luminal parasitic protists of clinical importance. *Clin Microbiol Rev* 15: 329–341.
31. Mank TG, Zaat JO, Blotkamp J, Polderman AM (1995) Comparison of fresh versus sodium acetate acetic acid formalin preserved stool specimens for diagnosis of intestinal protozoal infections. *Eur J Clin Microbiol Infect Dis* 14: 1076–1081.
32. Grendon JH, Digiacomio RF, Frost FJ (1991) *Dientamoeba fragilis* detection methods and prevalence: a survey of state public health laboratories. *Public Health Rep* 106: 322–325.
33. Verweij JJ, Stensvold CR (2014) Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections. *Clin Microbiol Rev* 27: 371–418.
34. Solaymani-Mohammadi S, Rezaian M, Babaei Z, Rajabpour A, Meamar AR, Pourbabai AA, Petri WA Jr (2006) Comparison of a stool antigen detection kit and PCR for diagnosis of *Entamoeba histolytica* and *Entamoeba dispar* infections in asymptomatic cyst passers in Iran. *J Clin Microbiol* 44: 2258–2261.
35. Stensvold CR, Arendrup MC, Mølbak K, Nielsen HV (2007) The prevalence of *Dientamoeba fragilis* in patients with suspected enteroparasitic disease in a metropolitan area in Denmark. *Clin Microbiol Infect* 13: 839–842.
36. Akhlaghi L, Shamseddin J, Meamar A, Razmjou E, Oormazdi H (2009) Frequency of intestinal parasites in Tehran. *Iran J Parasitol* 4: 44–47.
37. Rayan H, Ismail O, El Gayar E (2007) Prevalence and clinical features of *Dientamoeba fragilis* infections in patients suspected to have intestinal parasitic infection. *J Egypt Soc Parasitol* 37: 599–608.
38. de Wit dAS, Koopmans MPG, Kortbeek LM, van Leeuwen NJ, Vinjé J, van Duynhoven YTHP (2001) Etiology of gastroenteritis in sentinel general practices in The Netherlands. *Clin Infect Dis* 33: 280–288.
39. Ögren J, Dienus O, Löfgren S, Einemo IM, Iveroth P, Matussek A (2015) *Dientamoeba fragilis* prevalence coincides with gastrointestinal symptoms in children less than 11 years old in Sweden. *Eur J Clin Microbiol Infect Dis* 34: 1995–1998.
40. Norberg A, Nord CE, Evengård B (2003) *Dientamoeba fragilis*-a protozoal infection which may cause severe bowel distress. *Clin Microbiol Infect* 9: 65–68.
41. Stensvold CR, Lewis HC, Hammerum AM, Porsbo LJ, Nielsen SS, Olsen KEP, Arendrup MC, Nielsen HV, Mølbak K (2009) Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite. *Epidemiol Infect* 137: 1655–1663.
42. Stark D, Garcia LS, Barratt JLN, Phillips O, Roberts T, Marriott D, Harkness J, Ellis JT (2014) Description of *Dientamoeba fragilis* cyst and precystic forms from human samples. *J Clin Microbiol* 52: 2680–2683.
43. Rokni MB (2008) The present status of human helminthic diseases in Iran. *Ann Trop Med Parasitol* 102: 283–295.
44. Holtman GA, Kranenberg JJ, Blanker MH, Ott A, Lisman-van Leeuwen Y, Berger MY (2017) *Dientamoeba fragilis* colonization is not associated with gastrointestinal symptoms in children at primary care level. *Fam Pract* 34: 25–29.
45. Röser D, Simonsen J, Nielsen HV, Stensvold CR, Mølbak K (2015) History of antimicrobial use and the risk of *Dientamoeba fragilis* infection. *Eur J Clin Microbiol Infect Dis* 34: 1145–1151.
46. Jokelainen P, Hebbelstrup Jensen B, Andreassen BU, Petersen AM, Röser D, Krogfelt KA, Nielsen HV, Stensvold CR (2017) *Dientamoeba fragilis*, a commensal in children in Danish day care centers. *J Clin Microbiol* 55: 1707–1713.
47. Stensvold CR, Clark CG, Röser D (2013) Limited intra-genetic diversity in *Dientamoeba fragilis* housekeeping genes. *Infect Genet Evol* 18: 284–286.
48. Peek R, Reedecker FR, van Gool T (2004) Direct amplification and genotyping of *Dientamoeba fragilis* from human stool specimens. *J Clin Microbiol* 42: 631–635.
49. Cacciò SM, Sannella AR, Bruno A, Stensvold CR, David EB, Guimarães S, Manuali E, Magistrali C, Mahdad K, Beaman M, Maserati R, Tosini F, Pozio E (2016) Multilocus sequence typing of *Dientamoeba fragilis* identified a major clone with widespread geographical distribution. *Int J Parasitol* 46: 793–798.

Corresponding author

Elham Razmjou, Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, P.O. Box 15875–6171 Tehran Iran;
Phone: +98 21 88622653;
Fax: +98 21 88622653;
E-mail: razmjou.e@iums.ac.ir

Conflict of interests: No conflict of interests is declared.